Vancouver, BC — December 18, 2025 — Leads & Copy — LIR Life Sciences Corp. (CSE:SKNY) has announced the appointment of Dr. Peter Singer, a global health expert and former Special Advisor to the Director General of the World Health Organization (WHO), as a Scientific Advisor.
Dr. Singer brings over 25 years of experience in health innovation, public health policy, and global development. During his time at WHO, he played a key role in developing the organization’s global strategy and “triple billion” targets, as well as supporting implementation across programs and member states. His work focused on measurable country-level impact, coordination among multilateral health agencies, and aligning health investments with sustainable development goals.
Prior to WHO, Dr. Singer was the Chief Executive Officer of Grand Challenges Canada, where he oversaw CAD $450 million in funding to support over 1,000 health innovations across more than 90 countries. These initiatives were designed to address global health challenges with cost-effective solutions.
Dr. Singer’s academic background includes appointments as Professor of Medicine Emeritus at the University of Toronto and formerly Director of the Joint Centre for Bioethics, with research spanning medical ethics, health systems, and innovation policy. He has also received national and international honors, including the Michael Smith Prize as Canada’s Health Researcher of the Year in Population Health and Health Services, and appointment as an Officer of the Order of Canada for his contributions to global health and bioethics. He is a Fellow of the Royal Society of Canada, the Canadian Academy of Health Sciences, the U.S. National Academy of Medicine, and The World Academy of Sciences.
As Scientific Advisor, Dr. Singer will contribute to LIR’s strategy for expanding access to affordable obesity treatments globally. His expertise in health system innovation and equity-focused policy will support the Company’s mission to address the rising global burden of obesity with scalable solutions.
Edward Mills, CEO of LIR Life Sciences, stated that Dr. Singer’s experience leading international health initiatives and shaping health policy will be instrumental in making obesity treatment more accessible. Mills added that Dr. Singer’s understanding of translating innovation into measurable health impact aligns with the company’s mission.
LIR Life Sciences also announced the engagement of Venture Liquidity Providers Inc. (VLP) to provide market making services, effective immediately. VLP will trade common shares of LIR on the Canadian Securities Exchange (CSE) and other trading venues to maintain a reasonable market for the company’s shares.
Under the engagement terms, VLP will receive CAD$5,000 per month. The agreement is for three months and will automatically renew for successive one-month terms unless terminated. Either party can terminate the agreement with written notice after the initial term. Any prepaid monthly fees for months in which no trading occurred will be refunded within 15 business days upon termination.
Additionally, LIR’s Board of Directors has approved a grant of 2,220,000 Restricted Share Units (RSUs) to directors, officers, and consultants under the company’s equity incentive plan. The RSUs are subject to a four-month and one-day hold period, in accordance with securities laws and CSE rules. Each RSU entitles the holder to receive one common share of the Company upon vesting.
LIR Life Sciences is focused on researching and developing scalable and affordable treatments for obesity using novel drug delivery methods. The company is advancing a transdermal patch and other novel delivery systems that mimic GLP-1 to regulate appetite and blood sugar. LIR Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science.
Dr. Edward Mills,
Chief Executive Officer
Tel: +1 888 436 7772
Email: investors@lirlife.com
Source: LIR Life Sciences Corp.
